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Background: Virtually no studies on the dynamics of the intestinal microbiota in
patients admitted to the intensive care unit (ICU) are published, despite the increasingly
recognized important role of microbiota on human physiology. Critical care patients
undergo treatments that are known to influence the microbiota. However, dynamics
and extent of such changes are not yet fully understood. To address this topic, we
analyzed the microbiota before, during and after planned major cardio surgery that, for
the first time, allowed us to follow the microbial dynamics of critical care patients. In
this prospective, observational, longitudinal, single center study, we analyzed the fecal
microbiota using 16S rRNA gene sequencing.
Results: Samples of 97 patients admitted between April 2015 andNovember 2016were
included. In 32 patients, data of all three time points (before, during and after admission)
were available for analysis. We found a large intra-individual variation in composition of
gut microbiota. During admission, a significant change in microbial composition occurred
in most patients, with a significant increase in pathobionts combined with a decrease in
strictly anaerobic gut bacteria, typically beneficial for health. A lower bacterial diversity
during admission was associated with longer hospitalization. In most patients analyzed
at all three time points, the change in microbiota during hospital stay reverted to the
original composition post-discharge.
Conclusions: Our study shows that, even with a short ICU stay, patients present
a significant change in microbial composition shortly after admission. The unique
longitudinal setup of this study displayed a restoration of the microbiota in most patients
to baseline composition post-discharge, which demonstrated its great restorative
capacity. A relative decrease in benign or even beneficial bacteria and increase of
pathobionts shifts the microbial balance in the gut, which could have clinical relevance.
In future studies, the microbiota of ICU patients should be considered a good target
for optimisation.
Keywords: gut microbiota, intestinal microbiota, 16S rRNA gene sequencing, intensive care unit, critically ill,
longitudinal study
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INTRODUCTION
Infections are a major threat to critical care patients leading to
increased morbidity and mortality and require high antibiotic
consumption (Vincent et al., 2009). Although the merits of
antibiotics in this vulnerable population are undisputed, the
impact of antibiotic use on the host’s intestinal flora is an
important concern (Wischmeyer et al., 2016). Selective digestive
tract decontamination (SDD) is widely used as an infection
prevention measure in Intensive Care Units (ICUs) in the
Netherlands, leading to a mortality reduction compared to
standard care (de Smet et al., 2009). Benefits notwithstanding
(de Smet et al., 2009), SDD impacts the gut microbiota, by
suppressing Gram-negative potential pathogens, Staphylococcus
aureus (S. aureus) and yeasts, while maintaining anaerobic
populations through selective use of antibiotics, with unclear
clinical consequences (Benus et al., 2010). Besides antibiotics,
several other factors inherent to ICU stay are associated
with a disturbance in the host’s microbiota, also called
“dysbiosis,” where the balance between potentially pathogenic
and beneficial bacteria is aberrant (Kitsios et al., 2017).
These factors include a change in nutrition, non-antibiotic
pharmacological interventions (e.g., proton pump inhibitors
and vasopressors), and various invasive procedures including
endotracheal intubation and surgery (Krezalek et al., 2016;
Kitsios et al., 2017). Beneficial roles of the healthy gut
microbiota on human physiology are complex and include
nutrient metabolism, modulation of host immune responses
(Sekirov et al., 2010) and protection against potential pathogens
by competition (Harris et al., 2017). In a state of dysbiosis,
overgrowth of potential pathogens occurs which can lead to
inflammation and infection (Sekirov et al., 2010). Current
culture-independent techniques allow for an in-depth analysis of
the composition of gut microbiota (Sekirov et al., 2010; Harris
et al., 2017).
Despite increased recognition of the important role of
intestinal microbiota on health and disease (Harris et al.,
2017), few studies have been published on the dynamics of gut
microbiota in ICU patients using 16S rRNA gene sequencing
(Iapichino et al., 2008; Zaborin et al., 2014; McDonald et al.,
2016; Ojima et al., 2016; Yeh et al., 2016; Buelow et al., 2017;
Lankelma et al., 2017), generally involving acute admissions for
organ failure caused by infections, emergency surgery or trauma.
Most of these studies (Zaborin et al., 2014; McDonald et al., 2016;
Ojima et al., 2016; Yeh et al., 2016; Buelow et al., 2017; Lankelma
et al., 2017) utilize a case-control design and compare the gut
microbiota composition of ICU patients and healthy controls.
Small pilot studies (Iapichino et al., 2008; Zaborin et al., 2014;
Ojima et al., 2016; Buelow et al., 2017) as well as larger studies
(McDonald et al., 2016; Yeh et al., 2016; Lankelma et al., 2017)
suggest the evidence of rapid disruption of gut microbiota during
ICU stay associated with a loss of diversity and overgrowth
of potentially pathogenic micro-organisms, referred to here as
pathobionts (Iapichino et al., 2008). Previously published data
show that antibiotic-associated disturbance of microbiota can
take months to restore (Lankelma et al., 2015).
The purpose of this study was to evaluate the dynamics of
the composition of the gut microbiota in patients scheduled
for cardiac surgery before, during and after hospital admission.
Using 16S rRNA gene sequence analysis, we also evaluated
a correlation between composition of intestinal microbiota
and both baseline characteristics and clinical outcomes. We
observed that, despite a large inter-individual variability in
microbial composition at baseline, the composition of gut
microbiota during hospital stay showed a concordant pattern
toward decreasing microbial alpha diversity, with a relative
preponderance of potentially pathogenic species. This shift was
followed by full or partial post-discharge restoration. These
findings are in line with available literature (Dethlefsen et al.,
2008; Iapichino et al., 2008; Sekirov et al., 2010; Zaborin et al.,
2014).
MATERIALS AND METHODS
Study Population and Study Design
In this study, one hundred patients undergoing planned cardiac
surgery in the University Medical Center Groningen were
recruited between April 2015 and November 2016. Adult
patients, scheduled for cardiac surgery involving coronary
artery bypass graft (CABG) and/or valve surgery, screened in
our outpatient clinic preoperatively and admitted to the ICU
after surgery, were eligible for inclusion. Patient characteristics
and clinical data were recorded, including occurrence of
complications during ICU and hospital stay. Duration of hospital
stay included stay at peripheral hospitals for further recovery.
Antibiotic consumption from 3 months prior to inclusion
until 8 weeks after admission was documented. All patients
received peri-operative prophylaxis for 24 h with cefazolin or
clindamycin. On indication (expected length of stay (LOS) in
ICU ≥ 72 h and/or expected duration of mechanical ventilation
for≥ 48 h), SDD was prescribed, consisting of cefotaxime 1 gram
intravenously four times daily for 4 days and a topical application
of tobramycin, colistin and amphotericin B into the oropharynx
and stomach throughout ICU stay as described elsewhere
(de Smet et al., 2009). Patients colonized with Staphylococcus
aureus received intranasal mupirocin ointment pre-operatively
according to national protocol. We defined the following as
serious adverse outcomes: ICU- and in hospital-mortality,
increased (≥4 days) ICU length of stay (LOS), prolonged (≥2
days) duration of mechanical ventilation, and occurrence of
bacteraemia and post-operative wound infections, including
mediastinitis. If a patient had one or more of these adverse
outcomes, we defined this patient to have a combined adverse
outcome (CAO). Fecal samples were obtained by a research nurse
at ideally three time points: pre-admission on the day of pre-
operative screening (baseline or Time point 1, T1), once during
admission in the ICU or ward around day 4 (Time point 2, T2),
and post-admission at a post-discharge routine visit or home
visit (Time point 3, T3). All available samples were included for
analysis. All samples were stored directly at 4◦C and transferred
to −20◦C within 24 h; later, samples were stored at−80◦C until
further processing. All procedures performed in studies involving
human participants were in accordance with the ethical standards
of the institutional and/or national research committee and
with the 1964 Helsinki declaration and its later amendments or
comparable ethical standards. Ethical approval by the Medical
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Ethics Committee of our institution was received (approval
number METc2014/206). Informed consent was obtained from
all individual participants included in the study.
Microbiota Analysis; 16S rRNA Gene
Sequencing
DNA Extraction and MiSeq Preparation
From the stool sample, 0.25 g was used to extract the total DNA
as previously described (de Goffau et al., 2013). Subsequently,
the amplification of the V3–V4 region of the 16S rRNA
gene was performed using modified 341F and 806R primers
(Supplementary Material 1) containing a 6-nucleotide barcode
and flow-cell adaptor on the 806R primer as described
elsewhere (Bartram et al., 2011). A 2 × 300 cartridge (Illumina,
Eindhoven, the Netherlands) was used to perform both MiSeq
library preparation and sequencing. Supplementary Material 2
represents a detailed description of the PCR protocol, DNA
cleanup and the library preparation.
Analysis of Sequence Reads
The paired-end sequencing data received from Illumina software
were processed by the software PANDAseq (version 2.5) (Masella
et al., 2012) and QIIME (version 1.7.0) (Caporaso et al., 2010).
Readouts with a quality score below 0.9 were discarded by
PANDAseq to increase the quality of the sequence readouts.
De novo OTU-picking was performed without chimera filtering
with Greengenes (version 13.5) as reference database and ARB
software (version 5.5) using a SILVA database (version 123) was
used to check for contamination by the “kitome” on OTU level,
only negligible numbers were detected (Ludwig et al., 2004; de
Goffau et al., 2018).
Statistical Analysis
The calculation of alpha diversity (Shannon index) and beta
diversity was performed using R package “vegan” (version 2.5-4)
on the taxonomic level of genera. The associations of microbial
beta diversity vs. baseline and outcome characteristics were
calculated using adonis (permutational multivariate analysis of
variance using distance matrices), stratifying permutations for
multi-time points when comparing patient characteristics, or
stratifying by patients when associating beta diversity to time.
The statistical analysis of associations of baseline and outcome
patient characteristics vs. alpha diversity and microbial taxa were
performed using linear regression (“base” package for R) and
mixed models (package “lmerTest” v. 3.1-0), when including
time point or patient as random effects. The correction for false
discovery rate was applied considering the number of microbial
taxa included into analysis at the level of 5%, and was calculated
using the Benjamini-Hochberg method.
For each layer of microbiota (alpha diversity, beta diversity,
bacterial taxa), the association analysis of microbiome features
with baseline and clinical characteristics was performed on three
levels. On level one, we associated the microbial composition
against each of baseline and outcome characteristics adjusting
for age and sex. For alpha diversity and bacterial taxa, a
linear mixed-model approach was used with sampling time
(before, during or after admission, encoded as 3-level factor)
as random effect. For bacterial beta diversity, we stratified
permutations by time group using “strata” parameter for adonis
function (R package “vegan” v. 2.5–4). On level two, we re-
evaluated the associations between microbiota features with
clinical outcomes (CAO, LOS at the hospital, antibiotic post
discharge and therapeutic antibiotics), additionally adjusting for
all the baseline characteristics (age, gender, co-morbidities, BMI,
antibiotic pre-admission). On level three, we associated the
outcome measures with microbiota composition in each time
point separately.
The graphs weremadewith R package ‘ggplot2’ (version 3.1.1).
RESULTS
Inclusion of patients and collection of samples are summarized
in Figure 1. Detailed baseline characteristics and outcome
FIGURE 1 | Patient and sample flowchart.
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parameters are summarized in Table 1. Ninety-seven patients
were included. Pre-admission fecal samples were obtained from
92 patients, during admission at a median of 4 days post-
surgery (interquartile range (IQR), 3–5 days) from 53 patients;
and post-admission at a median of 71 days post-surgery
(IQR, 57–88 days) from 83 patients. From 32 patients, fecal
samples obtained at all time points were available for analysis.
Reasons for missing samples are shown in Figure 1. No patient
withdrew consent. Details on antibiotic consumption are listed
in Supplementary Material 3.
Lower Alpha Diversity Associated With
Longer Hospital Stay and Antibiotic Use
After Discharge
The microbial composition of fecal samples was determined
using 16S rRNA gene analysis. Bacterial diversity, measured as
Shannon index, significantly changed at T2 compared to baseline
(p = 0.02). A linear mixed-effect model was used to determine
associations between alpha diversity and patient baseline and
outcome characteristics. First, we tested each variable separately.
Length of hospital stay, use of SDD and use of antibiotics
post-discharge were found to be significantly associated with
the Shannon index (p < 0.05). When all these variables were
combined together in a single model, only length of hospital stay
and post-discharge antibiotic use remained significant; therefore,
it was tested which time point they were associated to. A lower
alpha diversity at T2 was associated with a longer hospital
stay (Figure 2A) and at T3 with antibiotic use after discharge
(Figure 2B).
The Microbiota Composition Shifts During
Admission but Reverts Back After
Discharge
Principal Coordinate Analysis (PCoA) (Figure 3) was performed
to identify a clustering pattern of the microbial compositions;
the baseline (T1) and post-admission (T3) samples were spread
over a large area in the PCoA plot, shifting from those taken
days after surgery (T2) with an overall significant change in
composition over time (p < 0.001). During admission, a shift
in composition of gut microbiota from baseline was seen
(p < 0.001), with an increase in principal component 1 and
a decrease in principal component 2, away from the original
profile. Plotted samples after discharge (T3) showed a difference
with T2 (p < 0.001). At T3 the samples seem to return to
the baseline situation in the PCoA plot indicating recovery of
the microbial composition, although statistically, there is still
a significant difference (p = 0.021). In order to determine
how much of the variance observed among patients could be
explained by the available baseline characteristics and outcomes,
the PERMANOVA analysis (Supplementary Material 4) was
performed.We looked into each time point to investigate how the
relative contribution of these characteristics would change during
the study period. We found that treatment with SDD could
explain almost 7% of the variation exhibited during admission
(T2), while the combined adverse outcome alone was accountable
for almost 5% at T2. The use of antibiotics during admission and
TABLE 1 | Baseline characteristics and outcome.
Variable N = 97
Age, years 68 [62–73]
Sex (male) 73 (75%)
BMI, kg/m2 27.5 ± 4.6
Planned operation
Coronary Artery Bypass Graft (CABG), N (%) 39 (40.2%)
CABG + Valve repair, N (%) 17 (17.5%)
Valve repair, N (%) 41 (42.3%)
Co-morbidity
Yes, N (%) 35 (36.1%)
Pulmonary disease 10 (10.3%)
Diabetes mellitus 22 (22.7%)
Chronic kidney failure 2 (2.1%)
Solid malignancy 4 (4.1%)
Hemato-oncologic malignancy 0 (0%)
Immunosuppression 2 (2.1%)
Alcohol/substance abuse 1 (1.0%)





APACHE IV 48 [39–57]
Exposure to antibiotics during admission
24 h of cefazolina 96 (99.0%)
SDDb 7 (7.2%)
≥ 1 day antibiotics 14 (14.4%)
Length of stay (LOS) Intensive Care Unit (ICU), days 1 [1–2]
LOS hospital, daysc 9 [8–13]
Need of vasopressors > 1 day 7 (7.2%)
Duration of mechanical ventilation
< 24 h (hrs) 92 (94.8%)
24–48 h 2 (2.1%)
2–5 days 1 (1.0%)
> 5 days 2 (2.1%)
Bacteraemia 3 (3.1%)
Peri-operative wound Infection 3 (3.1%)
Re-exploration 7 (7.2%)
Re-admission ICU 9 (9.3%)
Died during admission 1 (1.0%)
Combined adverse outcomed 13 (13.4%)




Data presented as median with [IQR], numbers with (%), or mean ± standard deviation,
as appropriate.
aOne additional patient received peri-procedural clindamycin due to penicillin allergy.
bSDD denotes Selective Decontamination of the Digestive tract. cAvailable in 94 patients.
dCombined adverse outcome defined as one or more of the following: ICU mortality,
in-hospital mortality, length of stay in ICU ≥ 4 days, duration of mechanical ventilation
≥ 2 days, occurrence of Post-Operative Wound Infection (POWI), including mediastinitis,
or bacteraemia.
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FIGURE 2 | The dot plots represent the association between the Shannon index at T2 and length of hospital stay (A) and the association between the Shannon index
at T3 and antibiotic use after discharge (B).
post-discharge, collectively, would explain 6% of variation of the
microbial composition after discharge (T3).
Associations Between Bacterial Taxa and
Patient Characteristics
Next, we performed the association study between bacterial
genera with baseline characteristics and outcome parameters,
results can be found in detail in Supplementary Material 5.
When estimating each of the baseline and outcome
characteristics separately (level 1), we observed associations
of several bacterial taxa with: (i) BMI, (ii) comorbidities
(immunosuppression, solid malignancy and chronic kidney
failure), (iii) therapeutic antibiotic use during admission
and (iv) hospital length of stay. When adjusting for baseline
characteristics (level 2), we observed associations with: (i) SDD,
(ii) the use of antibiotics during admission and (iii) hospital
length of stay.
Bacterial Dynamics Over Time
Figure 4 indicates that during the treatment timeline, strictly
anaerobic short-chain fatty acid-producing gut bacteria typically
beneficial for health, such as Faecalibacterium, Anaerostipes,
Blautia, and Roseburia (De Vos and de Vos, 2012; Rajilic-
Stojanovic and de Vos, 2014; Reichardt et al., 2018), decreased
significantly at T2. In contrast, pathobionts or members of oral
microbiota such as Enterococcus, Eggerthella, Peptococcus, and
Rothia (Weber and Gold, 2003; Zaura et al., 2009; Yeh et al., 2016;
Si et al., 2017; Ugarte-Torres et al., 2018), showed a substantial
increase at T2. Interestingly, the tendency to increase in T2 was
also observed for the obligate anaerobic gut microbes, such as
Akkermansia, Bifidobacterium, and Methanobrevibacter, which
are known to be the most stable in gut microbiota under external
perturbations and assumed dependent on host genetic makeup
(Goodrich et al., 2016) (Supplementary Material 6). Further, we
specifically looked at the dynamics of Enterobacteriaceae in the
SDD sub cohort. We found no consistent change over time,
however, at T2 the relative contribution was lower than 1% (data
not shown) in this group of patients.
Clinical Course and Gut Microbiota
Composition of Patients With the Lowest
Shannon Index
The dynamics of the gut microbiota composition in four patients
(#14, #40, #89, #98) who had the lowest Shannon index at T2 is
depicted in Figure 5. Patient #14 had a complicated course after
CABGwith sternal dehiscence, mediastinitis, sternal closure with
pectoralis major flaps, complicated by a wound infection, with
cultures yielding Enterobacter cloacae, S. aureus and Enterococcus
faecium, myocardial ischemia with decompensated heart failure
and S. aureus bacteraemia, needing prolonged treatment
with several classes of antibiotics (Supplementary Material 3),
also including treatment with SDD, a long hospital stay
and readmission. In this patient, the relative abundance of
Enterococcaceae was 82% at T2. In patient #40, who had an
uneventful clinical course, 60% of the gut microbiota was
dominated by Bifidobacteriaceae at T2, while at T1 and T3,
Bifidobacteriaceae’s contribution to the total flora was 4%. Patient
#89, who had a prolonged ICU stay due to shock caused by
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FIGURE 3 | Principal coordinate analysis of the microbial composition of the samples from ICU patients significantly changed over the course of the study period (p <
0.001). The different time points are depicted in purple (T1), yellow (T2) and blue (T3). Patients who did (7) and did not (90) receive SDD treatment are indicated with
open and closed symbols, respectively.
heart failure and subsequent renal failure, showed a relatively
high abundance of Bacteroidaceae (57%) at T2, while this was
8 and 5% at T1 and T3, respectively. Likewise, there was a
relatively high abundance of Enterococcaceae (18%) at T2; at T1
and T3 no Enterococcaceae were detected. Patient #98, with an
uneventful course, showed a remarkable relative abundance of
Enterobacteriaceae (16%) at T1, with a decrease to 10% at T2,
but an increase to 25% at T3, while at T2, a relative abundance
of Enterococcaceae (24%) was detected; this was 0% at T1 and T3.
DISCUSSION
Only few studies on the dynamics of intestinal microbiota in
critical care patients using culture-independent methods have
been published (Iapichino et al., 2008; Zaborin et al., 2014;
McDonald et al., 2016; Ojima et al., 2016; Yeh et al., 2016; Buelow
et al., 2017; Lankelma et al., 2017), despite evolving interest
in microbiota. Results provide a promising insight in potential
diagnostic and therapeutic possibilities for the prevention or cure
of infections (Harris et al., 2017; Kitsios et al., 2017). This is
the first prospective, observational longitudinal study analyzing
the dynamics of microbiota in patients receiving major elective
extra-intestinal surgery who post-operatively were admitted to
the ICU.
In order to analyse bacterial diversity, we included the
Shannon index. As previously reported and in line with other
studies (Lankelma et al., 2017), we found a significantly lower
Shannon index during than before admission. In our longitudinal
setup, we found the Shannon index after discharge not to
be significantly different from before admission. The main
differences were observed between the first two time points,
confirming that all interventions related to hospital admission for
elective surgery have a major impact on a patient’s microbiota.
The length of stay at the hospital was associated with a lower
Shannon index, especially in the microbiota sampled at T2,
suggesting the potential use of the gut microbiota data for an
intervention that might prevent post-surgery complications. A
lower Shannon index at T3 was associated with use of antibiotics
post-discharge indicating the strong effect that this therapy has
on the microbial gut diversity.
The gut microbial composition of patients before, during
and after admission showed a large intra-individual variability.
These changes occurred not only in patients with a complicated
course, but also in those with an uneventful post-operative
recovery. Relatively few patients (13 individuals, i.e., 13.4%)
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FIGURE 4 | The boxplot shows the results of the association analysis of the gut microbiota in ICU patients over time. In the top row a selection of beneficial
butyrate-producing gut bacteria (for details, cf. Supplementary Material 6) show a significant decrease during the stay at the intensive care unit. In the bottom row
we show bacteria that significantly increase during hospitalization of which Enterococcus is considered a pathobiont while the other two are regarded as beneficial to
gut health. In the analysis, only taxa remaining after application of FDR < 0.05 are considered significant and the p-value of the quadratic component of the model is
depicted in the headings.
had a predefined CAO. The median ICU stay was only 1
day, rendering this cohort to be different from the previous
studies on dynamics of microbiota in ICU patients involving
mainly acute admissions due to sepsis, surgery and trauma
(Iapichino et al., 2008; Zaborin et al., 2014; McDonald et al.,
2016; Ojima et al., 2016; Yeh et al., 2016; Buelow et al., 2017;
Lankelma et al., 2017). During hospital stay, we observed a
consistent pattern of changes in microbiota, characterized by:
(i) a substantial drop in abundance of many bacteria from the
Lachnospiraceae family, including the genera Blautia, Roseburia
and Dorea; (ii) an increase in potential pathobionts, including
enterococci; (iii) a relative increase in abundance of non-
pathogenic gut commensal genera known to be stable over
time, such as mucin-degrading Akkermansia, Bifidobacterium,
and the archeon Methanobrevibacter. Many factors potentially
responsible for variations in the microbiota composition may
contribute to the observed dynamic pattern (Zhernakova et al.,
2016; Kitsios et al., 2017). All patients were exposed to multiple
interventions including major surgery, dietary changes and
antibiotic use for at least a short period. Some patients had more
protracted courses with a longer ICU stay with use of SDD as
an infection prevention measure, longer courses of antibiotics,
and re-interventions. Although SDD is partially aimed at
Enterobacteriaceae, no significant change in their abundance was
seen in this small sub cohort likely due to sample size and possibly
due to the low relative contribution of Enterobacteriaceae to
the gut microbiota composition. The most pronounced dynamic
change of the gut microbiota during hospital stay in our cohort
is a decrease in abundance of bacterial members of healthy
microbiota, mostly butyrate producers. Taking into account their
roles as energy providers for colonocytes, together with their
known anti-inflammatory properties (Lankelma et al., 2015),
we postulate that this decrease in butyrate producers may have
a direct impact on clinical outcome. These results confirm
and complement previously published studies in disease- and
treatment-associated microbiota dynamics in different patient
cohorts (Iapichino et al., 2008; Zaborin et al., 2014; McDonald
et al., 2016; Ojima et al., 2016; Yeh et al., 2016; Buelow et al., 2017;
Lankelma et al., 2017).
In most patients analyzed at all time points, the change
in microbiota during hospital stay reverted to the original
composition post-discharge, showing the flexibility of the gut
microbiota and its great restorative capacity. We observed the
associations between microbial dynamics and clinical metadata
but they appear not to be clinically relevant. Our data thus
do not allow to state whether the microbial composition
at baseline could influence outcome and whether a state of
dysbiosis is a cause or an effect of critical illness. Dysbiosis was
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FIGURE 5 | The bar chart of selected samples represents the relative abundance of the main taxa, expressed at family level, in the gut microbiota of ICU patients
whose microbiota dramatically decreased according to their Shannon index during the stay at the ICU (A), and of ICU patients who had a stable Shannon index over
time (B).
previously found to be associated with an increased risk for
infection and adverse outcome. For instance, in a cohort of 301
medical ICU patients, disruption ofmicrobiota with Enterococcus
domination (≥30% relative abundance) as assessed by 16S rRNA
gene sequencing at ICU admission was associated with a 22%
increased risk for all-cause infection or death (Freedberg et al.,
2018). Additionally, dysbiosis is associated with chronic disease
states such as inflammatory bowel disease, obesity, diabetes and
cardiovascular disease (Wischmeyer et al., 2016). In case of
elective surgery, influencing or preventing a state of dysbiosis
before surgery might lead to a better outcome. The use of novel
probiotic strains to boost anaerobic butyrate-producing bacteria
could improve resilience to the effect of surgery and hospital stay
in general on the microbiota, or even simple nutritional advice
or supplementation with vitamins could improve the condition
of the patients’ microbiota. A possible role for fecal microbiota
transplantation (FMT) also merits consideration (McClave et al.,
2018); from a recent study, autologous FMT showed a more
rapid recovery than probiotics (Suez et al., 2018). Therefore,
“profiling” the microbiota of a patient before admission could
be of relevance. On the other hand, our data showed that
microbiota profiling during admission is much more promising
from a clinical perspective, due to its potential for predicting
post-surgery clinical outcomes, such as length of hospital stay.
The strength of this study is its longitudinal design: ideally,
patients were sampled three times, thereby serving as their own
control. This study has several limitations. We had a relatively
large number of missing fecal samples. Although in the context of
mentioned previously published studies our cohort was relatively
large, the sample size is still to be considered small. In future
studies, as noted by others (Lankelma et al., 2017), the use of
rectal swabs for sequencing could be an attractive alternative
especially in large-scale studies, with results similar to those
from stool samples (Budding et al., 2014). Differentiating the
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individual factors responsible for changes in intestinal microbiota
is not possible due to the omnipresent use of antibiotics. Also,
no (control) patient is withheld from surgery. We did not
assess the contribution of all factors potentially influencing the
intestinal microbiota composition of the patient, e.g., the use of
proton pump inhibitors was not evaluated (Kitsios et al., 2017).
Moreover, disentangling the many factors contributing to the
disruption of the intestinal microbiota composition is limited
by the inherent combination of some of these factors (Dickson,
2016); a patient with a prolonged course due to infectious
complications with hemodynamic instability will likely be treated
with prolonged antibiotics, possibly from different antibiotic
classes, for instance. How these individual factors contributed
to the observed association between length of hospital stay and
lower alpha diversity at T2, is therefore impossible to say in this
study design. Antibiotic use during stay in peripheral hospitals to
which patients with uncomplicated courses were transferred was
not documented. The use of 16S rRNA gene sequencing limits the
resolution of microbial data to the level of genera and, for some
taxonomic groups, species, and does not allow profiling bacterial
strains or identifying abundances of metabolic functions. Viruses
and fungi, although of presumed clinical relevance, were also
not targeted by this method. As this study was carried out in
a single center setting involving cardiac surgery patients, our
results might not be generalisable to all critical care patients.
However, despite these limitations, our project is a step forward
in understanding the dynamics of the microbiota and holds
promising views on potential diagnostic and therapeutic options
for ICU patients.
Our study shows that gut microbiota composition of elective
surgery patients admitted to the ICU undergoes significant
changes. The decrease in beneficial bacteria and the relative
increase of specific pathobionts shift the microbial balance to
dysbiosis in the gut, which has clinical relevance. Therefore,
optimizing themicrobiota of patients admitted to the ICU should
be considered in future studies.
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